Login to Your Account



Slow growth for Celgene's Otezla; Amgen reports hurricane expenses

By Karen Pihl-Carey
Analyst

Thursday, October 26, 2017

Shares of Celgene Corp. tanked on Thursday following the company's release of third-quarter financials, which included a slow growth for arthritis/psoriasis drug Otezla. Meanwhile, Amgen Inc. reported $67 million in pre-tax expenses due to Hurricane Maria's toll on the company's Puerto Rico-based manufacturing facility.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription